Norcliffe Capital provides more than capital to support their investments thanks to several decades of combined business experience in the life science sectors. Operating across the UK, they source companies with proven IP aiming to make a material impact in their industry, within a growing global market, where there is a clearly defined consumer need. Norcliffe investments are usually uncorrelated to the traditional investment markets and have a range of exit routes which offer the potential of generating positive investor returns.
We provide direct investment in ground-breaking medical technology and biotechnology companies.
about Norcliffe
2020
estd
Prior to his commercial activities David was Professor of Veterinary Pathology at the University of Glasgow and Director of the Leukaemia Research Fund’s Human Virus Centre.
David Onions is Norcliffe Capital’s science specialist, bringing decades of experience in life sciences and a proven track record of success in pioneering startups. A distinguished scientist with a PhD in Virology, David has held senior leadership positions in both research and commercial enterprises, shaping the landscape of biotechnology and life sciences investment.
Throughout his career, David has been instrumental in the success of multiple high-growth ventures, helping them navigate complex scientific and commercial challenges. As a former Chief Medical Officer at leading biotech firms, he played a pivotal role in the development of groundbreaking technologies and transformative therapies. His strategic guidance has led to the successful acquisition and growth of several life sciences startups, generating significant returns for investors.
David’s extensive network within the scientific and entrepreneurial communities provides Norcliffe Capital with unparalleled access to cutting-edge opportunities in the life sciences sector. His ability to identify transformative technologies, guide investment strategies, and mentor founders ensures that Norcliffe remains at the forefront of innovation.
At Norcliffe, David leverages his industry insights to assess emerging technologies, shape investment decisions, and drive the success of Norcliffe’s portfolio companies. His expertise, leadership, and vision continue to fuel Norcliffe’s mission to invest in breakthrough ideas with real-world impact.
Professor David Onions
CSO
With her unwavering dedication to supporting transformative innovations, Patricia is a driving force behind Norcliffe Capital’s success in the ever-evolving landscape of medtech and biotech investments.
Patricia is the visionary founder and Chief Executive Officer of Norcliffe Capital. With an impressive career spanning over 30 years in finance, Patricia brings a wealth of expertise in advisory, finance, and venture capital to her role.
Since 2013, Patricia has dedicated her efforts to pre-investment due diligence, equity fundraising under the EIS and SEIS schemes, and post-investment business management. Her transaction portfolio includes diverse industries such as life sciences, healthcare, technology and IoT.
Before venturing into the world of venture capital, Patricia spent 15 years at RBS, where she provided strategic financial advice for the corporate and commercial banking sectors. Her experience in these roles has honed her ability to navigate complex financial landscapes and identify promising investment opportunities.
Patricia’s commitment to excellence is evident in her pursuit of professional development, holding numerous financial qualifications. Her industry knowledge and insights make her a sought-after speaker at various industry events, where she shares her expertise and contributes to shaping the future of the medtech and biotech sectors.
Patricia Reynolds
Founder & CEO
Heart of the UK life science community
We believe in “Profit with a Purpose”.
Empowering innovation with integrity
Building partnerships that last
Norcliffe Capital has a strict investment mandate. Our investments must:
